AstaZeneca in patent warning as net profit falls

(AP)—Anglo-Swedish pharmaceutical company AstraZeneca PLC warned over expiring patents on its medicines as the company announced a 37 percent fall in full-year net profit on Thursday.

AstraZeneca said that its net profit fell to $6.3 billion in the year ended Dec. 31, compared with nearly $10 billion in 2011. The company blamed the loss of exclusivity on several big-name drugs for a drop in revenue to $28 billion from $33.6 billion a year earlier, and warned it expects the trend to continue hitting sales in 2013.

Chief executive Pascal Soriot said Thursday the company's 2012 performance "reflects a period of significant patent expiry and tough market conditions."

He said AstraZeneca's new leadership team would focus on the company's brands and developmental pipeline.

Patents are crucial assets for pharmaceutical companies, which use them to insulate their expensive, brand-name drugs from competition from cheap, generic versions. Expiring patents on several of AstraZeneca's top drugs translates to weaker revenue as the company cuts prices or surrenders market share.

AtraZeneca reported that U.S. revenue fell 21 percent, largely due to competition from of its anti-depression medication, Seroquel IR, whose patent expired last year.

The company said that nearly two thirds of its 19 percent loss in revenue in Western Europe was the result of generic competition for Seroquel IR, as well as drug Nexium, Atacand, and skin medication Merrem.

In Canada, to cholesterol-control drug Crestor dragged revenue down 31 percent.

The company said it expects challenging market conditions to persist in 2013, with the first quarter of the year expected to be "particularly challenging" since and —in Canada—haven't yet reached a full year since generics entered the market.

At Hargreaves Landsdowne, equity analyst Keith Bowman warned that, unlike other companies in the medical field, AstraZeneca "does not enjoy the cushion of alternative revenue streams such as consumer health care" and noted a "general lack of optimism" surrounding its developmental pipeline.

But Panmure analyst Savvas Neophytou said the results were "not as bad as they could have been," noting that fourth-quarter results were more resilient than expected.

AstraZeneca's fourth-quarter net profit edged higher to 1.52 billion pounds from 1.49 billion pounds in the same period a year earlier, while revenue slipped to 7.3 billion pounds from 8.7 billion pounds.

Stocks in fell 4.8 percent to 30 pounds a share in early morning trading on the London Stock Exchange.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Eli Lilly 2013 profit forecast tops expectations

Jan 04, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

Taiwan's HTC expects 30 percent sales plunge in 1Q

Feb 06, 2012

Taiwan's leading smartphone maker HTC forecast Monday that its revenue in the three months to March may plunge 30 percent from a year ago, as competitors Apple and Samsung take their grip on the market.

Texas Instruments lowers 4Q outlook

Dec 09, 2011

(AP) -- Semiconductor maker Texas Instruments Inc. lowered its outlook for its fourth-quarter revenue and profit on Thursday, saying demand had weakened for a variety of products that use its chips.

Amgen 4Q profit drops 16 pct. on higher spending

Jan 23, 2013

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Recommended for you

What are the chances that your dad isn't your dad?

9 hours ago

How confident are you that the man you call dad is really your biological father? If you believe some of the most commonly-quoted figures, you could be forgiven for not being very confident at all. But how ...

New technology that is revealing the science of chewing

Apr 15, 2014

CSIRO's 3D mastication modelling, demonstrated for the first time in Melbourne today, is starting to provide researchers with new understanding of how to reduce salt, sugar and fat in food products, as well ...

After skin cancer, removable model replaces real ear

Apr 11, 2014

(HealthDay)—During his 10-year struggle with basal cell carcinoma, Henry Fiorentini emerged minus his right ear, and minus the hearing that goes with it. The good news: Today, the 56-year-old IT programmer ...

Italy scraps ban on donor-assisted reproduction

Apr 09, 2014

Italy's Constitutional Court on Wednesday struck down a Catholic Church-backed ban against assisted reproduction with sperm or egg donors that has forced thousands of sterile couples to seek help abroad.

User comments